JPWO2017104706A1 - Brain-derived neurotrophic factor expression inducer and composition - Google Patents
Brain-derived neurotrophic factor expression inducer and composition Download PDFInfo
- Publication number
- JPWO2017104706A1 JPWO2017104706A1 JP2017556098A JP2017556098A JPWO2017104706A1 JP WO2017104706 A1 JPWO2017104706 A1 JP WO2017104706A1 JP 2017556098 A JP2017556098 A JP 2017556098A JP 2017556098 A JP2017556098 A JP 2017556098A JP WO2017104706 A1 JPWO2017104706 A1 JP WO2017104706A1
- Authority
- JP
- Japan
- Prior art keywords
- extract
- brain
- cocoon
- neurotrophic factor
- derived neurotrophic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title claims description 18
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title claims description 18
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 title claims description 9
- 239000000411 inducer Substances 0.000 title claims 4
- 239000000284 extract Substances 0.000 claims abstract description 50
- 230000001939 inductive effect Effects 0.000 claims abstract description 19
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 11
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 11
- 229940010454 licorice Drugs 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 8
- 241000269851 Sarda sarda Species 0.000 claims abstract description 8
- 239000004576 sand Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract 7
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 claims description 4
- 240000002234 Allium sativum Species 0.000 claims description 3
- 235000002723 Dioscorea alata Nutrition 0.000 claims description 3
- 235000007056 Dioscorea composita Nutrition 0.000 claims description 3
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 claims description 3
- 235000005362 Dioscorea floribunda Nutrition 0.000 claims description 3
- 235000004868 Dioscorea macrostachya Nutrition 0.000 claims description 3
- 235000005361 Dioscorea nummularia Nutrition 0.000 claims description 3
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 claims description 3
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 claims description 3
- 235000004611 garlic Nutrition 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 4
- 241000287462 Phalacrocorax carbo Species 0.000 claims 3
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 2
- 235000007794 yellow potato Nutrition 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 241000473391 Archosargus rhomboidalis Species 0.000 claims 1
- 244000132059 Carica parviflora Species 0.000 claims 1
- 235000014653 Carica parviflora Nutrition 0.000 claims 1
- 241001282110 Pagrus major Species 0.000 claims 1
- 244000299790 Rheum rhabarbarum Species 0.000 claims 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims 1
- 101150035467 BDNF gene Proteins 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 15
- 241000411851 herbal medicine Species 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000003925 brain function Effects 0.000 abstract description 11
- 230000007423 decrease Effects 0.000 abstract description 6
- 230000004770 neurodegeneration Effects 0.000 abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 6
- 208000020016 psychiatric disease Diseases 0.000 abstract description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000013305 food Nutrition 0.000 description 16
- 239000012676 herbal extract Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 240000004371 Panax ginseng Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 235000020710 ginseng extract Nutrition 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 244000000626 Daucus carota Species 0.000 description 6
- 235000002767 Daucus carota Nutrition 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000009372 dai-kenchu-to Substances 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000269333 Caudata Species 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940008396 carrot extract Drugs 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 229940069765 bean extract Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940126672 traditional medicines Drugs 0.000 description 2
- 241001671653 Aconitum carmichaelii Species 0.000 description 1
- 241001305711 Aconitum japonicum Species 0.000 description 1
- 244000141218 Alpinia officinarum Species 0.000 description 1
- 241001346320 Amomum villosum var. xanthioides Species 0.000 description 1
- 235000016500 Amomum xanthioides Nutrition 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001131796 Botaurus stellaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000510032 Ellipsaria lineolata Species 0.000 description 1
- 241000723281 Ephedra equisetina Species 0.000 description 1
- 241000723237 Ephedra intermedia Species 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000015030 Hedychium spicatum Nutrition 0.000 description 1
- 240000003237 Hedychium spicatum Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000269940 Pantodon buchholzi Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 241000960945 Rheum coreanum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241001643409 Sinomenium acutum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 241000123748 Uncaria macrophylla Species 0.000 description 1
- 241000157373 Uncaria rhynchophylla Species 0.000 description 1
- 241000214513 Uncaria sinensis Species 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000001774 alpinia officinarum Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- -1 feeds Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008954 quail grass Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
Abstract
【課題】BDNF遺伝子発現誘導能活性を有する生薬またはエキスを有効成分とする医薬又は組成物の提供を目的とする。
【解決手段】甘草、縮砂、何首烏、黄耆、葛根、山椒、赤芍、大黄、釣藤鉤、苦参、炮附子、麻黄、防已、良姜およびそれらのエキスは、BDNF遺伝子発現誘導活性を有し、それらを単独、混合、他の生薬を配合した漢方方剤は、うつ病やアルツハイマー病などの精神疾患や神経変性疾患による脳機能低下の改善に有用である。
【選択図】 図2An object of the present invention is to provide a pharmaceutical or a composition comprising a crude drug or extract having BDNF gene expression inducing activity as an active ingredient.
[Solution] Licorice, shredded sand, bonito, yellow cocoon, kudzu, yam, red cocoon, Daio, Chotou, bitter ginseng, cocoon, mao, proofed, Ryo and their extracts induce BDNF gene expression Kampo medicines that have activity and are combined alone or in combination with other herbal medicines are useful for improving brain function decline due to mental disorders such as depression and Alzheimer's disease and neurodegenerative diseases.
[Selection] Figure 2
Description
本発明は、脳由来神経栄養因子の発現を誘導する活性を有する生薬に関するものである。 The present invention relates to a crude drug having an activity of inducing expression of brain-derived neurotrophic factor.
我が国では、高齢化社会の影響により認知症などの神経系の疾患急増が問題視されている。
このような疾患による脳機能の低下は、患者本人の生活の質の重大な低下を招き、また介護に関わる家族の負担も増えるため、これら疾患の治療薬開発だけでなく、予防の観点からの研究開発は、精神衛生や社会福祉を考える上で非常に重要な取り組みである。
特に予防においては、日常的な服用が可能な薬剤の開発が求められる。
そこで注目されるのが、生薬に代表される伝統医薬品である。
これら伝統医薬品は、長年の使用実績から安全性の面で克服すべきハードルが低い一方、科学的根拠に乏しいものも少なくなく、特に中枢神経系への効果については未解明な部分が多い。
また、数多く存在する生薬の中から、脳機能低下の予防効果を有するものを検索することは、時間・労力・コストの面で非常に困難であるものの、例えば、生薬の人参、乾姜及び山椒の漢方方剤である大建中湯のマウスにおける記憶・学習増強効果(非特許文献1)、杏仁、麻黄、桂枝、人参、当帰、センキュウ、乾姜、甘草及び石膏からなる神経栄養因子合成促進剤(特許文献1)、薬用ニンジンのアルコール抽出物中の神経細胞賦活物質(特許文献2)などが報告されている。In Japan, the rapid increase in nervous system diseases such as dementia is regarded as a problem due to the effects of an aging society.
The decline in brain function due to such diseases leads to a significant decline in the quality of life of the patient and the burden on the family involved in nursing care. Therefore, not only the development of therapeutic drugs for these diseases, but also from the viewpoint of prevention. Research and development is a very important initiative when considering mental health and social welfare.
Particularly in prevention, development of drugs that can be taken on a daily basis is required.
Attention is paid to traditional medicines represented by crude drugs.
While these traditional medicines have low hurdles to be overcome in terms of safety due to many years of use, there are many that lack scientific evidence, and there are many unexplained parts in particular regarding their effects on the central nervous system.
In addition, it is very difficult to search for a drug having a preventive effect on brain function deterioration from a large number of herbal medicines in terms of time, labor, and cost. For example, ginseng, psoriasis and yam Daikenchuto, a Chinese herbal medicine, enhances memory and learning in mice (Non-patent Document 1), neurotrophic factor consisting of apricot kernel, mahuang, katsushi, ginseng, Toki, Senkyu, psoriasis, licorice and gypsum Synthesis accelerators (Patent Document 1), nerve cell activators (Patent Document 2) in alcoholic extracts of medicinal carrots and the like have been reported.
脳由来神経栄養因子(Brain-derived neurotrophic factor、以下、BDNFと称する)は、119個のアミノ酸からなるポリベプチドの二量体として存在し、神経栄養因子ファミリーに属するタンパク質の1つであり、その生理作用は、脳・神経系において、神経細胞の生存や神経ネットワーク形成、さらには記憶の固定化などの高次脳機能発現といった多岐にわたる。
また、様々な神経変性疾患や精神疾患においてBDNF発現量の減少が認められており、BDNFの発現を誘導する薬物、あるいはそれを含む組成物は、神経変性疾患や精神疾患により低下した脳機能を改善することが期待されている。
一方、長年の使用実績から安全性が確保されており、日本薬局方にも収載されている生薬のエキスにBDNF遺伝子発現誘導活性を持つものがどの程度存在するかが未知数である。Brain-derived neurotrophic factor (hereinafter referred to as BDNF) exists as a dimer of a polypeptide consisting of 119 amino acids, and is one of the proteins belonging to the neurotrophic factor family. In the brain / nervous system, the action is diverse, such as the survival of neurons, the formation of nerve networks, and the expression of higher brain functions such as memory fixation.
In addition, BDNF expression is decreased in various neurodegenerative diseases and psychiatric disorders, and a drug that induces BDNF expression or a composition containing the same has reduced brain function due to neurodegenerative diseases and psychiatric disorders. It is expected to improve.
On the other hand, safety has been ensured from long-term use results, and it is unknown how much of the herbal extracts that have BDNF gene expression inducing activity listed in the Japanese Pharmacopoeia.
上記した状況下、発明者らは、BDNF遺伝子発現変化をホタルの発光酵素ルシフェラーゼによる発光の強弱により計測可能な遺伝子改変マウス由来の大脳皮質神経細胞初代培養系を用いる測定系を開発し、この測定系により、神経細胞に作用してBDNF遺伝子発現を誘導する生薬エキスを簡便・迅速にスクリーニングすることに成功し、本発明を完成させるに至った。 Under the circumstances described above, the inventors developed a measurement system using a primary culture system of cerebral cortical neurons derived from a genetically modified mouse that can measure changes in BDNF gene expression by intensity of light emission by firefly luminescence enzyme luciferase. The system succeeded in simply and rapidly screening for a herbal extract that acts on nerve cells to induce BDNF gene expression, leading to the completion of the present invention.
本発明に使用される生薬は、甘草、縮砂、何首烏、黄耆、葛根、山椒、赤芍、大黄、釣藤鉤、苦参、炮附子、麻黄、防已及び良姜であり、個々の生薬については以下のとおりである。 The herbal medicines used in the present invention are licorice, shredded sand, bonito, yellow cocoon, kudzu, yam, red cocoon, dai yellow, choito tsubo, bitter ginseng, ginseng, mao, proof and good candy. The crude drugs are as follows.
甘草(カンゾウ):マメ科カンゾウ属ウラルカンゾウ(Glycyrrhiza uralensis)又はスペインカンゾウ(Glycyrrhiza glabra Linne)の根及びストロン、ときには周皮を除いたもの(皮去りカンゾウ)である。 Licorice: Glycyrrhiza uralensis or Glycyrrhiza glabra Linne roots and strons, sometimes excluding pericytes (peeled licorice).
縮砂(シュクシャ):ショウガ科アモムム属アモムム・キサンティオデス(Amomum xanthioides)の種子の塊である。 Shukusha: A seed mass of the genus Amomum xanthioides.
何首烏(カシュウ):タデ科タデ属ツルドクダミ(Polygonum multiflorum)の塊根である。 Kashuu: A tuberous root of the Polygonum multiflorum.
黄耆(オウギ):マメ科ゲンゲ属キバナオウギ(Astragalus membranaceus)又はナイモウオウギ(Astragalus mongholicus)の根である。 Jaundice: The root of the leguminous genus Astragalus membranaceus or Astragalus mongholicus.
葛根(カッコン):マメ科クズ属クズ(Pueraria lobata Ohwi)の周皮を除いた根である。 Kakkon: This is the root excluding the pericarp of Pueraria lobata Ohwi.
山椒(サンショウ):ミカン科サンショウ属サンショウ(Zanthoxylum piperitum)の成熟果実の果皮で、 種子をできるだけ取り除いたものである。 Salamander: Zanthoxylum piperitum mature fruit peel with as much seed as possible removed.
赤芍(セキシャク):ボタン科ボタン属シャクヤク(Paeonia lactiflora)の根であって、外皮をつけたままのものである。 Red peony: The root of the genus Paeonia lactiflora, with the outer skin still attached.
大黄(ダイオウ):タデ科ダイオウ属ダイオウ(Rheum palmatum)、タングートダイオウ(Rheum tanguticum)、ヤクヨウダイオウ(Rheum officinale)、チョウセンダイオウ(Rheum coreanum)又はそれらの種間雑種の根茎である。 Daihyo: Rheum palmatum, Rheum tanguticum, Rheum officinale, Rheum coreanum, or interspecific hybrids of rhododendrons.
釣藤鉤(チョウトウコウ):アカネ科カギカズラ属カギカズラ(Uncaria rhynchophylla)、トウカギカズラ(Uncaria sinensis Haviland)又はUncaria macrophylla Wallichの茎枝の一部をつけた棘である。 Chotochou: A spine with a part of the stem branch of Uncaria rhynchophylla, Uncaria sinensis Haviland, or Uncaria macrophylla Wallich.
苦参(クジン):マメ科クララ属クララ(Sophora flavescens)の根である。 Ginseng: The root of the leguminous family Clara (Sophora flavescens).
炮附子(ホウブシ):キンポウゲ科トリカブト属ハナトリカブト(Aconitum carmichaeli)又はオクトリカブト (Aconitum japonicum)の塊根をニガリ液に数日浸し、加熱処理したものである。 Bamboo bud: A tuber of Aconitum carmichaeli or Aconitum japonicum is immersed in bittern for several days and heat-treated.
麻黄(マオウ):マオウ科マオウ属シナマオウ(Ephedra sinica)、アイマオウ(Ephedra intermedia)又はキダチマオウ(Ephedra equisetina)の地上茎である。 Mao: The ground stalk of Ephedra sinica, Ephedra intermedia or Ephedra equisetina.
防已(ボウイ):ツヅラフジ科ツヅラフジ属オオツヅラフジ(Sinomenium acutum)のつる性の茎及び根茎である。 Protected (bowie): A vine stem and rhizome of the genus Sinomenium acutum.
良姜(リョウキョウ):ショウガ科ハナミョウガ属リョウキョウ(Alpinia officinarum)の根茎である。 Ryokyo: Rhizome of Alpinia officinarum.
本発明には、上記した生薬の抽出物(以下、「エキス」称する)を用いることもできる。
エキスの製造方法としては、生薬を、例えば、水(温水、熱湯など)によって抽出するか、又は有機溶媒を用いて抽出する。
有機溶媒としては、例えば、メタノール、エタノールなどのアルコール類、ポリエチレングリコール、プロピレングリコール、ブチレングリコールなどのグリコール類、アセトニトリルなどを用いることができ、これらの有機溶媒を単独、又は適宜組み合わせ、一定の比率で混合して用いることができる。
好ましくは、メタノール、エタノール、水、ブチレングリコール、含水アルコール又はアセトニトリル−水混合溶媒などが好ましい。In the present invention, the above-described herbal extract (hereinafter referred to as “extract”) can also be used.
As a method for producing the extract, the herbal medicine is extracted with, for example, water (hot water, hot water, etc.) or extracted with an organic solvent.
As the organic solvent, for example, alcohols such as methanol and ethanol, glycols such as polyethylene glycol, propylene glycol and butylene glycol, acetonitrile and the like can be used, and these organic solvents are used alone or in appropriate combination, and a certain ratio. Can be mixed and used.
Preferably, methanol, ethanol, water, butylene glycol, hydrous alcohol, acetonitrile-water mixed solvent, or the like is preferable.
水抽出又は有機溶媒抽出の方法としては、通常の生薬抽出に用いられる方法を用いることができ、例えば、生薬1重量部に対し、水及び/又は有機溶媒5〜300重量部を用いて、攪拌しながら、その沸点以下の温度で加熱還流することが望ましい。
抽出工程は、通常は5分〜7日間、好ましくは10分〜24時間実施すればよい。As a method of water extraction or organic solvent extraction, a method used for normal herbal medicine extraction can be used. For example, 5 to 300 parts by weight of water and / or organic solvent is used for 1 part by weight of herbal medicine and stirred. However, it is desirable to heat and reflux at a temperature below the boiling point.
The extraction step is usually performed for 5 minutes to 7 days, preferably 10 minutes to 24 hours.
抽出工程終了後、濾過又は遠心分離などの適当な方法により、水及び/又は有機溶媒抽出液から、不溶物を分離して粗エキスを得ることができる。
常法による熱水エキス又は有機溶媒エキスの他に、粗エキスを各種有機溶媒又は吸着剤などにより、更に処理した精製エキスも、本発明に用いることができる。
これらの粗エキス及び各種の精製処理を終えた精製エキスは、抽出したままの溶液、溶媒を濃縮したもの、溶媒を留去し乾燥したもの、凍結乾燥したもの、さらに乾燥した固形物を粉砕し粉末等にしたもののいずれであってもよい。After completion of the extraction step, a crude extract can be obtained by separating insolubles from water and / or an organic solvent extract by an appropriate method such as filtration or centrifugation.
In addition to the hot water extract or organic solvent extract according to a conventional method, a purified extract obtained by further treating the crude extract with various organic solvents or adsorbents can also be used in the present invention.
These crude extracts and purified extracts that have been subjected to various purification treatments are prepared by pulverizing the extracted solution, the solvent concentrated, the solvent evaporated to dryness, the freeze-dried, and the dried solid. Any of powders and the like may be used.
本発明に使用される甘草、縮砂、何首烏、黄耆、葛根、山椒、赤芍、大黄、釣藤鉤、苦参、炮附子、麻黄、防已、良姜及びそれらのエキスは、各々単独で使用してもよく、組み合わせて処方として使用してもよい。
単独での使用は、何首烏、山椒、赤芍、釣藤鉤または良姜が好ましく、特に山椒が好ましい。
処方には、人参など他の生薬を加えた処方としてもよい。
例えば、人参エキスを加えた処方として、後述する試験例4の山椒エキス+人参エキス、防已エキス+人参エキス、釣藤鈎エキス+人参エキスなどが挙げられ、また、大建中湯に用いられる、人参、山椒および乾姜の組み合わせなどが例として挙げられる。The licorice, shredded sand, bonito, jade, katsune, yam, red cocoon, red sardine, Daio, Choto, ginseng, ginseng, mao, proofed, and potatoes used in the present invention are each independent. Or may be used in combination as a prescription.
As for the use alone, it is preferable to use a garbage, a yam, a red carp, a fishing wisteria or a good carp.
The prescription may include other herbal medicines such as carrots.
For example, prescriptions with ginseng extract include yam extract + carrot extract, gauze extract + carrot extract, ginseng extract + ginseng extract of Test Example 4 to be described later, and also used for Daikenchuyu. For example, a combination of carrots, yam, and dried ginger.
上記の単味エキス及びエキスを組み合わせた処方物は、錠剤,散剤、顆粒剤、カプセル剤などに製剤化して経口的に投与してもよい。 The above simple extract and a combination of extracts may be formulated into tablets, powders, granules, capsules and the like and administered orally.
経口剤は、必要に応じて結合剤、滑沢剤、崩壊剤、着色剤、矯味剤などを加え錠剤、散剤、顆粒剤、カプセル剤を常法により製造することができる。
また、必要に応じて防腐剤、抗酸化剤、安定化剤などを添加することができる。For oral preparations, tablets, powders, granules, and capsules can be produced by conventional methods by adding a binder, lubricant, disintegrant, coloring agent, corrigent and the like as necessary.
Moreover, antiseptic | preservative, antioxidant, a stabilizer, etc. can be added as needed.
エキス等の投与量は、疾患、症状、年齢、併用される治療的措置などにより異なるが、経口剤としてヒトに投与する場合は、抽出物として0.1〜100mg/kgを1日1回〜数回に分けて投与すればよい。 The dose of extract and the like varies depending on the disease, symptoms, age, therapeutic measures used in combination, etc., but when administered to humans as an oral preparation, 0.1 to 100 mg / kg as an extract once a day It may be administered in several divided doses.
エキス等を、該エキス等含有した飲食品または飲食品用組成物にすることもできる。
ここで、「飲食品」とは、飲食品全般を意味するが、いわゆる健康食品を含む一般食品の他、厚生労働省の保健機能食品制度に規定された特定保健用食品や栄養機能食品などの保健機能食品をも含むものであり、更にサプリメント、飼料、食品添加物等も本発明の飲食品に包含される。An extract or the like can be made into a food or drink or a composition for food or drink containing the extract or the like.
Here, “food and drink” means food and drink in general, but in addition to general foods including so-called health foods, health foods such as foods for specified health use and nutritional function foods stipulated in the health functional food system of the Ministry of Health, Labor and Welfare. Functional foods are also included, and supplements, feeds, food additives and the like are also included in the food and drink of the present invention.
エキス等を飲食品または飲食品用組成物に使用するには、そのまま、又は種々の栄養成分とともに加工肉、果汁、牛乳、豆乳などの飲食品の原料に混ぜて飲食品または飲食品用組成物を製造することができる。
また、エキス等を健康食品、栄養補助食品などとして使用する場合、例えば慣用の手段を用いて、錠剤、カプセル、散剤、顆粒、懸濁剤、シロップ剤などの形態に調製することができる。In order to use an extract or the like in a food or drink or a composition for food or drink, the food or drink or the composition for food or drink as it is or mixed with raw materials of food or drink such as processed meat, fruit juice, milk, soy milk together with various nutritional components Can be manufactured.
Moreover, when using an extract etc. as a health food, a nutritional supplement, etc., it can prepare in forms, such as a tablet, a capsule, a powder, a granule, a suspension agent, a syrup, using a conventional means, for example.
上記の飲食品または飲食品用組成物におけるエキス等の配合量は、添加形態及び投与形態によっても異なり広い範囲から選択できるが、通常、0.01〜10重量%配合するのが望ましい。 The blending amount of the extract or the like in the above food or drink or the composition for food or drink varies depending on the addition form and dosage form and can be selected from a wide range, but it is usually desirable to blend 0.01 to 10% by weight.
甘草、縮砂、何首烏、黄耆、葛根、山椒、赤芍、大黄、釣藤鉤、苦参、炮附子、麻黄、防已、良姜及びそれらのエキスは、BDNF遺伝子発現誘導活性を有し、それらを単独、混合、他の生薬を配合した漢方方剤は、軽度認知障害(MCI)や認知症などの疾患による脳機能の低下の改善や予防、うつ病やアルツハイマー病などの精神疾患や神経変性疾患による脳機能の改善に有用である。 Licorice, shredded sand, bonito, yellow cocoon, kudzu, yam, red fox, Daio, Chotou, bitter melon, cocoon, mao, banned, Ryoji and their extracts have BDNF gene expression inducing activity Kampo medicines, alone or in combination with other herbal medicines, can improve or prevent brain function deterioration due to diseases such as mild cognitive impairment (MCI) and dementia, mental disorders such as depression and Alzheimer's disease Useful for improving brain function due to neurodegenerative diseases.
以下、本発明を試験例で説明するが、本発明はこれらに限定されるものではない。
試験例で使用した生薬エキスは、生薬を純水で50分間煎じ、ろ過後、凍結乾燥したエキス粉末をMilliQ水に溶解させたものである(10mg/mL)。Hereinafter, although this invention is demonstrated by a test example, this invention is not limited to these.
The herbal extract used in the test example is obtained by decocting herbal medicine with pure water for 50 minutes, filtering, and then dissolving the freeze-dried extract powder in MilliQ water (10 mg / mL).
試験例1
<BDNF遺伝子発現誘導能活性>
BDNF遺伝子発現誘導活性は、BDNF遺伝子発現変化を発光強度により計測可能な遺伝子改変マウス(BDNF−Lucマウス)を用いて検討した。
胎生16.5日齢のBDNF−Lucマウスの大脳皮質を単離後、酵素処理し、得られた細胞を96ウェル培養プレート上で13日間培養した。
培養後、生薬エキスを終濃度が0.5mg/mLとなるように培養液中に添加し、再び培養を行った。
実験対照群としては、溶媒であるMilliQ水のみを添加した。MilliQ水又は生薬エキスの添加後、6時間、24時間、48時間後にルシフェラーゼ活性測定キット(プロメガ社)を用いて各ウェルの発光を測定した。各時間におけるMilliQ水添加時のルシフェラーゼ活性を基準として、生薬エキスのルシフェラーゼ活性の誘導倍率を算出した。
生薬エキスのルシフェラーゼ活性の誘導倍率を表1に示す。Test example 1
<BDNF gene expression inducing activity>
The BDNF gene expression inducing activity was examined using a genetically modified mouse (BDNF-Luc mouse) capable of measuring changes in BDNF gene expression based on luminescence intensity.
The cerebral cortex of embryonic day 16.5 day old BDNF-Luc mice was isolated, treated with enzymes, and the resulting cells were cultured on a 96-well culture plate for 13 days.
After the culture, the herbal extract was added to the culture solution so that the final concentration was 0.5 mg / mL, and the culture was performed again.
As an experimental control group, only MilliQ water as a solvent was added. Luminescence of each well was measured using a luciferase activity measurement kit (Promega) 6 hours, 24 hours and 48 hours after the addition of MilliQ water or herbal extract. Based on the luciferase activity when MilliQ water was added at each time, the induction ratio of the luciferase activity of the herbal extract was calculated.
Table 1 shows the induction ratio of the luciferase activity of the crude drug extract.
表1の結果から、ルシフェラーゼ活性の誘導倍率が10倍以上となったものは、カシュウ(何首烏)、サンショウ(山椒)、セキシャク(赤芍)、チョウトウコウ(釣藤鉤)、ボウイ(防已)、及びリョウキョウ(良姜)であった。
そのうち、カシュウ、サンショウ、チョウトウコウは15倍を超えていた。
最大は、チョウトウコウの21.29培である。
また、5倍〜10倍の値を示したものはダイオウ(大黄)、マオウ(麻黄)及びニンジン(人参)であった。From the results shown in Table 1, those in which the induction ratio of luciferase activity was 10 times or more were: Kashou (What's Necklace), Salamander (Yamabuchi), Sekishaku (Akaban), Butterflyfish (Tsujido), Bowie (Present) ), And Ryokyo.
Among them, cashew, salamander and butterfly were more than 15 times.
The maximum is 21.29 cultivated butterfly.
Moreover, the thing which showed the value of 5 times-10 times was Daio (large yellow), Maou (mao yellow), and the carrot (carrot).
試験例2
<内在性BDNF遺伝子発現誘導活性>
内在性BDNF遺伝子(大脳皮質神経細胞で実際に発現しているBDNF遺伝子)発現誘導活性は、RT−qPCR法によりBDNF mRNA発現量の変化を測定することで検討した。
胎生17日齢のラットの大脳皮質を単離後、酵素処理し、得られた細胞を6ウェル培養プレート上で13日間培養した。
培養後、各生薬エキスを終濃度が0.5mg/mLとなるように培養液中に添加し、再び培養を行った。
実験対照群としては、溶媒であるMilliQ水のみを添加した。
各生薬エキスの添加後、0時間、0.5時間、1時間、3時間、6時間、9時間、12時間、24時間、36時間、48時間、72時間後にRNA抽出キット(キアゲン社)を用いて細胞からRNAを抽出し、Superscript II Reverse Transcriptase(インビトロジェン社)を用いて逆転写反応を行った。
逆転写反応後に得られたDNA産物及びSYBR Select Master Mix(アプライドバイオシステムズ社)を用いて、各生薬エキス添加後のBDNF mRNA発現量の変化を解析した。
結果を図2に示す。
図2に示したグラフから、コントロール(溶媒)に比較して人参エキス、サンショウエキス、釣藤鉤エキスのいずれも高い内在性BDNF遺伝子発現誘導活性を示した。
特に釣藤鉤エキスは、高い値を示した。Test example 2
<Endogenous BDNF gene expression inducing activity>
Endogenous BDNF gene (BDNF gene actually expressed in cerebral cortical neurons) expression-inducing activity was examined by measuring changes in the BDNF mRNA expression level by RT-qPCR method.
The cerebral cortex of a 17-day-old rat was isolated and then subjected to enzyme treatment, and the resulting cells were cultured on a 6-well culture plate for 13 days.
After the culture, each herbal extract was added to the culture solution so that the final concentration was 0.5 mg / mL, and the culture was performed again.
As an experimental control group, only MilliQ water as a solvent was added.
After the addition of each herbal extract, after 0 hours, 0.5 hours, 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, RNA extraction kit (Qiagen) RNA was extracted from the cells, and a reverse transcription reaction was performed using Superscript II Reverse Transcriptase (Invitrogen).
Using the DNA product obtained after the reverse transcription reaction and SYBR Select Master Mix (Applied Biosystems), changes in the BDNF mRNA expression level after the addition of each herbal extract were analyzed.
The results are shown in FIG.
From the graph shown in FIG. 2, the ginseng extract, the salamander extract, and the Choito extract all showed higher endogenous BDNF gene expression-inducing activity than the control (solvent).
In particular, Choito extract showed a high value.
試験例3
何首烏エキス、大黄エキス、麻黄エキス、良姜エキス、防已エキスを使用し、試験例2と同様な方法で、内在性BDNF遺伝子発現誘導活性を検討した。結果を図3に示した。
図3のグラフから、いずれも高い内在性BDNF遺伝子発現誘導活性を示し、特に大黄エキス、麻黄エキス及び良姜エキスが高い値を示した。Test example 3
By using the same koji extract, large yellow extract, hemp yellow extract, bean extract, and anti-prevented extract, the endogenous BDNF gene expression inducing activity was examined in the same manner as in Test Example 2. The results are shown in FIG.
From the graph of FIG. 3, all showed high endogenous BDNF gene expression-inducing activity, and especially the large yellow extract, the maize extract and the bean extract showed high values.
試験例4
人参エキスに山椒エキス、防已エキス、または釣藤鉤エキスを混合した場合の内在性BDNF遺伝子発現誘導活性は、RT−qPCR法によりBDNF mRNA発現量の変化を測定することで検討した。
胎生17日齢のラットの大脳皮質を単離後、酵素処理し、得られた細胞を6ウェル培養プレート上で13日間培養した。
培養後、各生薬エキスを終濃度が0.5mg/mLとなるように培養液中に添加し、再び培養を行った。
人参エキスと山椒エキス、および人参エキスと防已エキスの組み合わせの場合は添加3時間後、人参エキスと釣藤鉤エキスの組み合わせの場合は添加24時間後にRNA抽出キット(キアゲン社)を用いて細胞からRNAを抽出し、Superscript II Reverse Transcriptase(インビトロジェン社)を用いて逆転写反応を行った。
逆転写反応後に得られたDNA産物およびSYBR Select Master Mix(アプライドバイオシステムズ社)を用いて、各生薬エキス添加後のBDNF mRNA発現量の変化を解析した。
結果を図4に示した。
図4に示したグラフから、各生薬単独よりも人参エキスと組み合せた方が高い誘導活性を示すことが明らかになった。Test example 4
Endogenous BDNF gene expression inducing activity when ginseng extract, yaoi extract, or Choto extract was mixed was examined by measuring changes in BDNF mRNA expression level by RT-qPCR method.
The cerebral cortex of a 17-day-old rat was isolated and then subjected to enzyme treatment, and the resulting cells were cultured on a 6-well culture plate for 13 days.
After the culture, each herbal extract was added to the culture solution so that the final concentration was 0.5 mg / mL, and the culture was performed again.
In the case of the combination of ginseng extract and yam extract, and in the case of the combination of ginseng extract and anti-prevented extract, the cells are extracted using an RNA extraction kit (Qiagen Co., Ltd.) 3 hours after addition, and in the case of the combination of ginseng extract and Choito extract, 24 hours after addition. RNA was extracted from the DNA, and reverse transcription reaction was performed using Superscript II Reverse Transcriptase (Invitrogen).
Using the DNA product obtained after the reverse transcription reaction and SYBR Select Master Mix (Applied Biosystems), changes in the BDNF mRNA expression level after the addition of each herbal extract were analyzed.
The results are shown in FIG.
From the graph shown in FIG. 4, it was revealed that the combination with carrot extract showed higher inductive activity than each herbal medicine alone.
試験例5
<大建中湯エキスのBDNF遺伝子発現誘導能活性>
BDNF遺伝子発現誘導活性は、BDNF遺伝子発現変化を発光強度により計測可能な遺伝子改変マウス(BDNF−Lucマウス)を用いて検討した。
胎生16.5日齢のBDNF−Lucマウスの大脳皮質を単離後、酵素処理し、得られた細胞を96ウェル培養プレート上で13日間培養した。
培養後、大建中湯エキスを終濃度が0.5mg/mLとなるように培養液中に添加し、再び培養を行った。
大建中湯エキスの添加後、6時間、24時間後にルシフェラーゼ活性測定キット(プロメガ社)を用いて各ウェルの発光を測定した。
結果を図5に示した。
図5に示したグラフから、大建中湯即ち人参、山椒、及び乾姜の組み合せにおいても高い活性を示すことが明らかになった。Test Example 5
<BDNF gene expression inducing activity of Daikenchuto extract>
The BDNF gene expression inducing activity was examined using a genetically modified mouse (BDNF-Luc mouse) capable of measuring changes in BDNF gene expression based on luminescence intensity.
The cerebral cortex of embryonic day 16.5 day old BDNF-Luc mice was isolated, treated with enzymes, and the resulting cells were cultured on a 96-well culture plate for 13 days.
After the culture, Daikenchuto extract was added to the culture solution so that the final concentration was 0.5 mg / mL, and the culture was performed again.
Luminescence of each well was measured using a luciferase activity measurement kit (Promega) 6 hours and 24 hours after the addition of Daikenchuto extract.
The results are shown in FIG.
From the graph shown in FIG. 5, it was revealed that Daikenchuyu, that is, carrot, yam, and dried rice cake also showed high activity.
甘草、縮砂、何首烏、黄耆、葛根、山椒、赤芍、大黄、釣藤鉤、苦参、炮附子、麻黄、防已、良姜及びそれらのエキスは、BDNF遺伝子発現誘導活性を有し、それらを単独、混合、他の生薬を配合した漢方方剤は、認知症などの疾患による脳機能の低下の改善や予防、うつ病やアルツハイマー病などの精神疾患や神経変性疾患による脳機能の低下の改善に有用である。
また、甘草、縮砂、何首烏、黄耆、葛根、山椒、赤芍、大黄、釣藤鉤、苦参、炮附子、麻黄、防已及び/又は良姜のエキスは、単独、混合又は他の生薬を配合して、認知症などの疾患による脳機能の低下の改善や予防、うつ病やアルツハイマー病などの精神疾患や神経変性疾患による脳機能の低下を改善する食品又は飲料とすることができる。Licorice, shredded sand, bonito, yellow cocoon, kudzu, yam, red cocoon, Daihuang, Chotou, ginseng, 炮 子, 麻黄, 防 已, 良姜 and their extracts have BDNF gene expression inducing activity Kampo medicines, alone or in combination with other herbal medicines, can improve and prevent brain function deterioration due to diseases such as dementia, brain function due to mental disorders such as depression and Alzheimer's disease, and neurodegenerative diseases. Useful for improving the decline.
In addition, the extract of licorice, shredded sand, bonito, yellow cocoon, kudzu, yam, red cocoon, Daihuang, Chotou, bitter ginseng, garlic, mao, proofed and / or Ryokan extract, alone, mixed or other Combining herbal medicines, it can be used as a food or beverage that improves or prevents brain function decline due to diseases such as dementia, and improves brain function decline due to mental or neurodegenerative diseases such as depression or Alzheimer's disease. .
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015247942 | 2015-12-18 | ||
JP2015247942 | 2015-12-18 | ||
PCT/JP2016/087237 WO2017104706A1 (en) | 2015-12-18 | 2016-12-14 | Agent and composition for inducing expression of brain-derived neurotrophic factor |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2017104706A1 true JPWO2017104706A1 (en) | 2018-10-04 |
Family
ID=59056781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017556098A Ceased JPWO2017104706A1 (en) | 2015-12-18 | 2016-12-14 | Brain-derived neurotrophic factor expression inducer and composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2017104706A1 (en) |
WO (1) | WO2017104706A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108186966A (en) * | 2018-03-26 | 2018-06-22 | 横琴恩健生物科技有限公司 | A kind of composition for preventing or improving senile dementia and its application |
KR102532914B1 (en) * | 2022-11-29 | 2023-05-18 | 권혁분 | Composition for preventing and treating dementia and Manufacturing method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0725777A (en) * | 1993-07-14 | 1995-01-27 | Tsumura & Co | Synthesis promoter for neurotrophy factor |
JP2009221188A (en) * | 2008-02-19 | 2009-10-01 | Gifu Seratsuku Seizosho:Kk | Composition |
JP2011504884A (en) * | 2007-11-30 | 2011-02-17 | チイヨウフン | Pharmaceutical composition for the treatment of depression and anxiety |
JP2012102059A (en) * | 2010-11-12 | 2012-05-31 | Ogawa & Co Ltd | Antidepressant |
CN102716459A (en) * | 2012-05-08 | 2012-10-10 | 四川中方制药有限公司 | Chinese medicinal composition for treating senile mild cognitive impairment and preparation method thereof |
CN104208265A (en) * | 2014-09-19 | 2014-12-17 | 陈建福 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
CN104687442A (en) * | 2015-02-04 | 2015-06-10 | 南安市荣兴专利技术转移中心有限公司 | Healthcare underwear capable of preventing and treating diabetes |
-
2016
- 2016-12-14 WO PCT/JP2016/087237 patent/WO2017104706A1/en active Application Filing
- 2016-12-14 JP JP2017556098A patent/JPWO2017104706A1/en not_active Ceased
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0725777A (en) * | 1993-07-14 | 1995-01-27 | Tsumura & Co | Synthesis promoter for neurotrophy factor |
JP2011504884A (en) * | 2007-11-30 | 2011-02-17 | チイヨウフン | Pharmaceutical composition for the treatment of depression and anxiety |
JP2009221188A (en) * | 2008-02-19 | 2009-10-01 | Gifu Seratsuku Seizosho:Kk | Composition |
JP2012102059A (en) * | 2010-11-12 | 2012-05-31 | Ogawa & Co Ltd | Antidepressant |
CN102716459A (en) * | 2012-05-08 | 2012-10-10 | 四川中方制药有限公司 | Chinese medicinal composition for treating senile mild cognitive impairment and preparation method thereof |
CN104208265A (en) * | 2014-09-19 | 2014-12-17 | 陈建福 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
CN104687442A (en) * | 2015-02-04 | 2015-06-10 | 南安市荣兴专利技术转移中心有限公司 | Healthcare underwear capable of preventing and treating diabetes |
Non-Patent Citations (11)
Title |
---|
BEHAVIOURAL BRAIN RESEARCH, vol. 210, JPN6021026400, 2010, pages 171 - 177, ISSN: 0004777450 * |
BMC COMPLEMENTARY & ALTERNATIVE MEDICINE, vol. 12, no. 188, JPN6022019066, 2012, pages 1 - 18, ISSN: 0004777451 * |
BRITISH JOURNAL OF PHARMACOLOGY, vol. 166, no. 6, JPN6020045992, 2012, pages 1872 - 1887, ISSN: 0004777447 * |
ENVIRONMENTAL TOXICOLOGY ANDPHARMACOLOGY, vol. 38, no. 1, JPN6020045988, 2014, pages 257 - 262, ISSN: 0004777445 * |
J.CENT.SOUTH UNIV.(MED.SCI.), vol. 31, no. 2, JPN6021026401, 2006, pages 194 - 199, ISSN: 0004777449 * |
JOURNAL OF ETHNOPHARMACOLOGY, vol. 132, no. 2, JPN6020045986, 2010, pages 393 - 399, ISSN: 0004777444 * |
JOURNAL OF GINSENG RESEARCH, vol. 28, no. 2, JPN6020045995, 2004, pages 94 - 103, ISSN: 0004777446 * |
JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 122, JPN6022019065, 2013, pages 257 - 269, ISSN: 0004777452 * |
JOURNAL OF TRADITIONAL CHINESE MEDICALSCIENCES, vol. 1, no. 1, JPN6020045982, 2014, pages 28 - 37, ISSN: 0004777442 * |
中国老年学雑誌, vol. 31, JPN6021026402, 2011, pages 4834 - 4836, ISSN: 0004777448 * |
医学と生物学, vol. 155, no. 9, JPN6020045984, 2011, pages 602 - 606, ISSN: 0004777443 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017104706A1 (en) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumari et al. | Rauvolfia serpentina L. Benth. ex Kurz.: phytochemical, pharmacological and therapeutic aspects | |
JP2001514650A (en) | Essential oil composition | |
Fierascu et al. | Leonurus cardiaca L. as a source of bioactive compounds: an update of the European medicines agency assessment report (2010) | |
JP6004419B2 (en) | Foods and beverages containing β-secretase inhibitors and β-secretase inhibitors | |
KR102400607B1 (en) | Pharmaceutical and Health Functional Food Composition for Prevention or Treatment of Cancer Comprising Extracts of Herbal Medicine Mixture | |
JP2023522299A (en) | Compositions and methods for treating solid and soft tissue tumors and proliferative diseases | |
Mortazavian et al. | Antiproliferative effect of viola tricolor on neuroblastoma cells in vitro | |
WO2017104706A1 (en) | Agent and composition for inducing expression of brain-derived neurotrophic factor | |
EP2260855A1 (en) | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same | |
KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
KR101721696B1 (en) | Pharmaceutical composition containing combination extract of Moutan Root Bark, Angelica Dahurica Root and Bupleurum Root and fractions thereof for prevention and treatment of neurodegenerative disorder | |
KR101987418B1 (en) | A composition comprising herbal mixture extract for neuroprotection | |
WO2022075096A1 (en) | Raldh2 expression enhancing agent | |
CN103768171A (en) | Traditional Chinese medicinal composition for resisting depression, sterilizing and disinfecting and preparation method of composition | |
CN104435298B (en) | A kind of medicine composition for treating depression | |
CN104768875A (en) | Process for bio synthesis of nano arsenic trioxide and its use in treatment of diseases including cancers | |
Semalty et al. | Herbal drugs in chronic fatigue syndrome: an overview | |
KR20180015795A (en) | A composition having activity of aldose reductase inhibition comprising the purified extract of agrimonia pilosa | |
Kaushik et al. | Studying the Ethno-Pharmacological Basis of Antiepileptic Activity of Medhya Rasayanas-A Nootropic Package From Ayurveda | |
CN105193887A (en) | Acanthopanax senticosus extract and antioxidation application thereof | |
JP2007084559A (en) | Blood testosterone level-lowering inhibitor | |
Sathya et al. | Bioactive compounds with neuropharmacological properties from medicinal plants-a brief review | |
Palasuwan et al. | Total antioxidant activity of Thai medicinal plants associated with the treatment of cardiovascular diseases, diabetes and cancers | |
KR101667873B1 (en) | Pharmaceutical composition for prevention or treatment of Parkinson's disease comprising herbal extract or fraction thereof | |
JP2024056288A (en) | Neurodegenerative disease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220523 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220920 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221101 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20230329 |